Last reviewed · How we verify
VB-111 + bevacizumab
VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.
VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF. Used for Glioblastoma.
At a glance
| Generic name | VB-111 + bevacizumab |
|---|---|
| Sponsor | Vascular Biogenics Ltd. operating as VBL Therapeutics |
| Drug class | Antiangiogenic agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting VEGF, VB-111 and bevacizumab aim to reduce angiogenesis and tumor growth. VB-111's mechanism is based on its ability to bind to and inhibit the expression of VEGF mRNA, whereas bevacizumab directly binds to VEGF, preventing it from interacting with its receptor.
Approved indications
- Glioblastoma
Common side effects
- Hypertension
- Nausea
- Fatigue
Key clinical trials
- VB-111 in Surgically Accessible Recurrent/Progressive GBM (PHASE2)
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme (PHASE1, PHASE2)
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |